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1. Introduction 
Recently, an adult-type neuronal storage disease, 
characterized bymyoclonus, cerebellar ataxia, con- 
vulsive seizure, cherry red spots, skeletal dysplasia, 
mild gargoyle face, angiokeratoma and inguinal hernia 
was reported as 'A late form of familial amaurotic 
idiocy' [1] or 'Mucolipidosis' [2] and this disease is 
transmitted asautosomal recessive trait. Enzymatic 
study of this disease revealed ecreased activity of 
/3-galactosidase in leukocytes and cultured skin fibro- 
blasts and suggested this disease was GM1 gangliosi- 
dosis [31. However, this possibility was ruled out by 
lipid analysis of affected sympathetic ganglia which 
showed marked accumulation ofGM3 and GM2 
ganglioside and not GM1 ganglioside [3]. Together 
with accumulation ofganglioside in the nervous 
system, an increase of sialyl oligosaccharides in the 
urine of the patient [3] led us to study the sialyl 
compound metabolism in cultured fibroblasts and 
leukocytes. We report here a defect of c~-N-acetyl- 
neuraminidase with increase of sialyl compound in 
fibroblasts of a patient with this disorder. 
2. Materials and methods 
Reagents: N-acetylneuraminic acid (NANA), fetuin 
(type III) and sialyllactose (type II) were obtained 
from Sigma Chemical Co., St. Louis. Sialyllactose 
was separated into two structural isomers, a-N-acetyl- 
Abbreviations: GLC, gas-liquid chromatography; TLC, thin- 
layer chromatography 
neuraminosyl-(2-+3)-lactose and a-N-acetylneura- 
minosyl-(2~6)-lactose by the method in [4]. [3H]- 
sialyllactitol was obtained from New England Nuclear, 
Dreieich. (Content of radiochemical isomers: a-N- 
acetylneuraminosyl-(2~3)-lactitol, 90%; a-N-acetyl- 
neuraminosyl-(2~6)-lactitol, 10%; Spec act. 17.5/aCi/ 
/~mol.) 
Fibroblasts were cultured from a skin biopsy of a 
patient with adult-type neuronal storage disease and 
normal controls. Clinical details of the patient were 
reported separately [31. Sialic acid content of the 
tissue was determined by the method in [5], and 
protein was determined by the method in [61. 
GM3 ganglioside sialidase was assayed by the 
method in [7] with slight modification. We used 
GM3 ganglioside, tritiated at the sphingosine base, as 
a substrate. After incubation, liberated lact osylceramide 
was separated from GM3 ganglioside by TLC and the 
radioactivity of lactosylceramide was determined by a 
liquid scintillation counter. GDla ganglioside sialidase 
was assayed as follows: The 100/~1 incubation volume 
contained 10 nmol [3H]GDla ganglioside (spec. act. 
61/aCi//amol), cell homogenate containing 100/~g 
protein and 15/~mol acetate buffer (pH 4.2). The 
mixture was incubated for 1 h at 37°C and the [3H]- 
GM1 ganglioside formed, was determined by the 
method in [8]. Fetuin sialidase activity was assayed 
by the method in [9]. The sialic acid, liberated from 
fetuin was measured by GLC method [10] or mass 
fragmentography (M.S. et al., in preparation). Sialyl- 
lactose sialidase activity was assayed by the method 
in [11] for lysosomal sialidase, using c~-N-acetyl- 
neuraminosyl-(2-+3)-lactose. Lib rated sialic acid was 
measured as above. Sialyllactitol sialidase was assayed 
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Table 1 
Sialidase activity with GM~ and GDla ganglioside 
Leukocytes Fibroblasts 
GM 3 GDla GM~ GDla 
Patient 0.64 1.48 _+ 0.35 a 0.12 0.58 -+ 0.16 a 
Control (n=4) 0.56 -+ 0.09 1.69 -+ 0.28 0.14 -+ 0.01 0.49 -+ 0.26 
a Mean value of 4 determinations 
Enzyme activity: nmol/mg protein/h 
as follows: The 100/~1 incubation volume contained 
100 nmol [3H]sialyllactitol, cell homogenate con- 
taining 100-390 gg protein and 15/amol acetate 
buffer (pH 4.2). The mixture was incubated for 1 h 
at 37°C and the [3H]lactitol formed, was determined 
by the method in [12]. 
3. Results 
GM3 ganglioside and GDla ganglioside sialidase 
activity were normal in both fibroblasts and leuko- 
cytes of the patient (table 1). Total sialic acid content 
of cultured fibroblasts from the patient was increased 
to 2.4-fold of normal control (table 2). Activity of 
fetuin sialidase was assayed by incubation for 24 h at 
37°C. Profound deficiency of this enzyme was found 
in the fibroblasts of the patient (table 3). Activity of 
the sialyUactose sialidase was assayed by incubation 
for 12 h at 37°C, using a-N-acetylneuraminosyl- 
(2-->3)-lactose asa substrate. This enzyme was also 
deficient in the fibroblasts of the patient (table 3). 
In addition, sialidase deficiency was confirmed with 
[3H]sialyllactitol as a substrate in the fibroblasts of 
the patient (table 3). 
Table 2 
Sialic acid content of fibroblasts 
nmol NANA/mg protein 
Patient 17.1 -+ 3.9 a 
Control (n=8) 7.l -+ 1.8 
a Mean value of duplicate determinations of4 different sub- 
cultures 
Table 3 
Sialidase activity of fibroblasts with sialyllactose, 
[ aH]sialyllactitol and fetuin 
Sialyllactose Sialyllactitol Fetuin 
Patient 0.1 0.32 +- 0.04 a 0.04 
Control (n=4) 4.1 -+ 0.9 6.8 -+ 0.7 3.7 -+ 1.0 
a Mean value of 4 determinations 
Enzyme activity: nmol/mg protein/h 
4. Discussion 
We examined one patient with an adult-type 
neuronal storage disease whose clinical and pathological 
findings were reported in [3]. 
Analytical data suggested that GM3 ganglioside 
was accumulated in the sympathetic ganglia [3], and 
sialic acid content in skin cultured fibroblasts and 
sialyl oligosaccharides in urine were increased in the 
patient [3]. From these findings, the disturbances of 
sialyl compounds (ganglioside, sialyl glycoprotein or 
sialyl oligosaccharide) were supposed to exist in the 
patient. 
The activities of the GM3 ganglioside and GDla 
ganglioside sialidases were not decreased in this disease 
and the accumulation of GM3 ganglioside was found 
not attributable to the primary defect of this sialidase. 
Similar ganglioside accumulation i neurons was 
reported in Hurler's syndrome [13 16] and muco- 
polysaccharidosis III [ 17], but the relationship of the 
lipid disturbance to the primary defect of mucopoly- 
saccharide metabolism remained unclear. 
The sialidase activities using fetuin, c~-N-acetyl- 
neuraminosyl-(2-->3)-lactose and ~-N-acetylneur- 
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aminosyl-(2~3)-lactitol as substrates were severely 
decreased in the cultured fibroblasts of the patient. 
The terminal oligosaccharide structure of fetuin was 
reported to be a-N-acetylneuraminosyl-(2-+3)-/3- 
galactosyl-(l~4)-N-acetylglucosamine [ 18]. This data 
suggests an a-neuraminidase, which hydrolyses the 
~-N-acetylneuraminosyl-(2-+3)-galactoside m iety of 
sialyl oligosaccharides and glycoproteins, is deficient 
in this disease. 
Recently, patients with neuraminidase deficiency 
have been reported [19,20] who had the same neurol- 
ogical findings as our case, but lacked bony deformity 
and/3-galactosidase deficiency, which were character- 
istic of our case. In contrast o our case, fetuin 
sialidase activity remained about 1/4th of normal 
control in their case. This discrepancy in this enzyme 
activity may explain the clinical differences in these 
two disorders. 
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